Vaccination in India: Air Commodore Subramanian Shankar said, 'This is the largest study in India so far to assess the effect of the Covid vaccine.' He informed, 'The sample size in other studies has been less than 10 lakhs.
New Delhi. There is good news for those taking the Covishield vaccine. According to the interim results of a recent study, there has been a 93 percent reduction in the cases of breakthrough infections among those taking this Oxford-AstraZeneca vaccine. In this study, 15.9 lakh health and frontline workers of the Indian Armed Forces were included. It is being said that it is also included in the major studies done around the world regarding the vaccine. Breakthrough infection means becoming a victim of the same disease even after vaccination, to avoid which the vaccine has been taken.
What was found in the study
The study said, 'The data of 15 lakh 95 thousand 6302 people (average age 27.6 years) were analyzed for more than 135 days. By May 30, 95.4% had received partial and 82.2% complete vaccination. According to the study, 10 thousand 61 cases of breakthrough infection were seen in people without vaccination, while this figure was 1 thousand 159 in partially vaccinated and 2 thousand 512 among those who were fully vaccinated. At the same time 37, 16, and 7 deaths occurred in all three categories respectively. 'The corrected vaccine effectiveness against the infection was 91.8-94.9 percent.'
In this study, anonymized data taken from the health surveillance system of the armed forces were used. This system was further improved to monitor Covid-19. The system contained data on vaccination, date of infection with COVID-19, and death related to COVID.
The researchers said the study was published in a special issue of the peer-reviewed medical journal Armed Forces India ('Covishield (AZD1222) Vaccine effectiveness among healthcare and frontline workers of Indian Armed Forces: Interim results of VIN-WIN cohort study'). The data provides insight into the major benefits of vaccination against breakthrough infections and deaths.
In a conversation with the Indian Express, Air Commodore Subramanian Shankar said, 'This is India's largest study so far to assess the effect of the Kovid vaccine.' He informed, 'The sample size in other studies has been less than 10 lakhs. He said that therefore we think that the study of VIN-WIN is potentially the largest among the studies done on the effect of the vaccine.